OMNISCAN 287 MG — DIN 02172771
GADODIAMIDE : 287 MG · GE HEALTHCARE CANADA INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is OMNISCAN?
OMNISCAN 287 MG contains GADODIAMIDE : 287 MG. It is listed in the Health Canada Drug Product Database under DIN 02172771, held by GE HEALTHCARE CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 19-Oct-2006. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OMNISCAN used for?
Contrast enhancement for MRI of CNS lesions (adults/pediatrics); MRI of thoracic, abdominal, pelvic, breast, retroperitoneal, and musculoskeletal lesions (adults); MRA of renal/aorto-iliac arteries.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Gadodiamide cost around the world?
Gadodiamide is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Bahrain publishes a retail (max); Hungary publishes a producer price (ex-factory); Saudi Arabia publishes a public. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 2 | 6 | SAR███.██ |
| South Africa | single exit price | 4 | 4 | ZAR███.██ |
| Hungary | producer price (ex-factory) | 1 | 3 | HUF███.██ |
| Bahrain | retail (max) | 1 | 2 | BHD███.██ |
15 pack listings across 8 brand entries and 4 price bases, refreshed 03 Sep 2026. Ranges span every Gadodiamide pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Gadodiamide in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Gadodiamide, across 2 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GE HEALTHCARE CANADA INC | 1 | 1 | OMNISCAN | Sourceable in Canada |
| SANOFI CANADA, INC. | 1 | 0 | OMNISCAN LIQ IV 287MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 287 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 10 mL vial, 15 mL fill in 20 mL vial, and 20 mL vial; all in boxes of 10. |
| Storage | Not explicitly detailed in provided text snippet (Section 11 mentioned in TOC but text cuts off). Standard practice: Draw into syringe and use immediately. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Gadodiamide |
|---|---|
| ATC code | V08CA03 |
| AHFS class | 36:89.00* ; See footnote |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02172771 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2172771 |
| Brand name | OMNISCAN |
| Generic / active ingredient | GADODIAMIDE : 287 MG |
| Market authorization holder | GE HEALTHCARE CANADA INC |
| Health Canada schedule | Ethical |
| ATC code | V08CA03 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08CA |
| Current status | MARKETED |
| Status date | 19-Oct-2006 |
| Original market date | 1997-03-25 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
CNS: 0.1 mmol/kg (0.2 mL/kg). Body: 0.3 mmol/kg (0.6 mL/kg). MRA: 0.1 mmol/kg (0.2 mL/kg). Administer as bolus IV injection. Use lowest effective dose. Flush with 5 mL saline.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Chronic severe renal insufficiency (GFR <30 mL/min/1.73m2); acute kidney injury; neonates up to 4 weeks of age; hypersensitivity to gadodiamide or any ingredient in the formulation.
Warnings and precautions
NOT FOR INTRATHECAL USE (fatal reactions). Risk of Nephrogenic Systemic Fibrosis (NSF). Gadolinium accumulation in brain. Risk of anaphylactoid/hypersensitivity reactions.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 2 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OMNISCAN LIQ IV 287MG/ML | 287 MG | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | 02093197 |
2 · Same class — other molecules in ATC V08CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Gadobutrol | GADOVIST 1.0 · PIXXOSCAN | 2 | 2 | Yes |
| Gadopentetic Acid | GADOPENTETATE DIMEGLUMINE INJECTION · GADOPENTETATE DIMEGLUMINE INJECTION, USP · MAGNEVIST | 3 | 1 | Yes |
| Gadodiamide | OMNISCAN · OMNISCAN LIQ IV 287MG/ML | 2 | 1 | Yes |
| Gadoteridol | PROHANCE | 2 | 1 | Yes |
| Gadobenic Acid | MULTIHANCE | 1 | 1 | Yes |
| Gadoteric Acid | DOTAREM | 1 | 1 | Yes |
| Gadoxetic Acid | PRIMOVIST | 1 | 1 | Yes |
| Gadoversetamide | OPTIMARK | 5 | 0 | Not in Canada |
| Gadofosveset | ABLAVAR · VASOVIST | 2 | 0 | Not in Canada |
| Mangafodipir | TESLASCAN | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.